Triple-negative breast cancer (TNBC) is aggressive and lacks standard hormone or HER2 therapies. Learn how immunotherapy, PARP inhibitors, antibody-drug conjugates, and personalized vaccines are transforming treatment in 2025.
Read More
Triple-negative breast cancer (TNBC) is aggressive and lacks standard hormone or HER2 therapies. Learn how immunotherapy, PARP inhibitors, antibody-drug conjugates, and personalized vaccines are transforming treatment in 2025.
Read More